These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

268 related items for PubMed ID: 8784089

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Therapy for 6.5-7.5 years with recombinant insulin-like growth factor I in children with growth hormone insensitivity syndrome: a clinical research center study.
    Backeljauw PF, Underwood LE, GHIS Collaborative Group. Growth hormone insensitivity syndrome.
    J Clin Endocrinol Metab; 2001 Apr; 86(4):1504-10. PubMed ID: 11297575
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Changes in serum insulin-like growth factor I (IGF-I) and IGF-binding protein-3 levels during growth hormone treatment in prepubertal short children born small for gestational age.
    Boguszewski M, Jansson C, Rosberg S, Albertsson-Wikland K.
    J Clin Endocrinol Metab; 1996 Nov; 81(11):3902-8. PubMed ID: 8923836
    [Abstract] [Full Text] [Related]

  • 8. The short-term effects of growth hormone therapy on height velocity and cardiac ventricular wall thickness in children with Noonan's syndrome.
    Cotterill AM, McKenna WJ, Brady AF, Sharland M, Elsawi M, Yamada M, Camacho-Hübner C, Kelnar CJ, Dunger DB, Patton MA, Savage MO.
    J Clin Endocrinol Metab; 1996 Jun; 81(6):2291-7. PubMed ID: 8964866
    [Abstract] [Full Text] [Related]

  • 9. Recombinant insulin-like growth factor (IGF)-I treatment in short children with low IGF-I levels: first-year results from a randomized clinical trial.
    Midyett LK, Rogol AD, Van Meter QL, Frane J, Bright GM, MS301 Study Group.
    J Clin Endocrinol Metab; 2010 Feb; 95(2):611-9. PubMed ID: 19880790
    [Abstract] [Full Text] [Related]

  • 10. Insulin-like growth factor I improves height in growth hormone insensitivity: two years' results.
    Ranke MB, Savage MO, Chatelain PG, Preece MA, Rosenfeld RG, Blum WF, Wilton P.
    Horm Res; 1995 Feb; 44(6):253-64. PubMed ID: 8808010
    [Abstract] [Full Text] [Related]

  • 11. Dose-response study of biosynthetic human growth hormone (GH) in GH-deficient children: effects on auxological and biochemical parameters. Dutch Growth Hormone Working Group.
    de Muinck Keizer-Schrama SM, Rikken B, Wynne HJ, Hokken-Koelega AC, Wit JM, Bot A, Drop SL.
    J Clin Endocrinol Metab; 1992 Apr; 74(4):898-905. PubMed ID: 1548357
    [Abstract] [Full Text] [Related]

  • 12. Is insulin-like growth factor-1 monitoring useful in assessing the response to growth hormone of growth hormone-deficient children?
    Lanes R, Jakubowicz S.
    J Pediatr; 2002 Nov; 141(5):606-10. PubMed ID: 12410186
    [Abstract] [Full Text] [Related]

  • 13. Double blind trial comparing the effects of two doses of growth hormone in prepubertal patients with chronic renal insufficiency.
    Hokken-Koelega AC, Stijnen T, De Jong MC, Donckerwolcke RA, De Muinck Keizer-Schrama SM, Blum WF, Drop SL.
    J Clin Endocrinol Metab; 1994 Oct; 79(4):1185-90. PubMed ID: 7525628
    [Abstract] [Full Text] [Related]

  • 14. A randomized, double blind, placebo-controlled trial on safety and efficacy of recombinant human insulin-like growth factor-I in children with growth hormone receptor deficiency.
    Guevara-Aguirre J, Vasconez O, Martinez V, Martinez AL, Rosenbloom AL, Diamond FB, Gargosky SE, Nonoshita L, Rosenfeld RG.
    J Clin Endocrinol Metab; 1995 Apr; 80(4):1393-8. PubMed ID: 7536209
    [Abstract] [Full Text] [Related]

  • 15. Insulin-like growth factor-I treatment in primary growth hormone insensitivity: effect of recombinant human IGF-I (rhIGF-I) and rhIGF-I/rhIGF-binding protein-3 complex.
    Tonella P, Flück CE, Mullis PE.
    Horm Res Paediatr; 2010 Apr; 73(2):140-7. PubMed ID: 20190552
    [Abstract] [Full Text] [Related]

  • 16. Effects of insulin-like growth factor I treatment on statural growth, body composition and phenotype of children with growth hormone insensitivity syndrome. GHIS Collaborative Group.
    Underwood LE, Backeljauw P, Duncan V.
    Acta Paediatr Suppl; 1999 Feb; 88(428):182-4. PubMed ID: 10102077
    [Abstract] [Full Text] [Related]

  • 17. Yearly stepwise increments of the growth hormone dose results in a better growth response after four years in girls with Turner syndrome. Dutch Working Group on Growth Hormone.
    van Teunenbroek A, de Muinck Keizer-Schrama SM, Stijnen T, Jansen M, Otten BJ, Delemarre-van de Waal HA, Vulsma T, Wit JM, Rouwé CW, Reeser HM, Gosen JJ, Rongen-Westerlaken C, Drop SL.
    J Clin Endocrinol Metab; 1996 Nov; 81(11):4013-21. PubMed ID: 8923853
    [Abstract] [Full Text] [Related]

  • 18. A 5-year prospective study of growth hormone (GH)-deficient children treated with GH before the age of 3 years. French Serono Study Group.
    Rappaport R, Mugnier E, Limoni C, Crosnier H, Czernichow P, Leger J, Limal JM, Rochiccioli P, Soskin S.
    J Clin Endocrinol Metab; 1997 Feb; 82(2):452-6. PubMed ID: 9024235
    [Abstract] [Full Text] [Related]

  • 19. The response to treatment with pituitary growth hormone: the New Zealand experience.
    Livesey JH, Cuneo RC, Donald RA, Harris RG, Ibberston HK, Costello JM, Holdaway IM, Gluckman PD, Fraser TR, Chapman GE.
    N Z Med J; 1989 Aug 09; 102(873):399-402. PubMed ID: 2761875
    [Abstract] [Full Text] [Related]

  • 20. Short children born small for gestational age and treated with growth hormone for three years have an important catch-down five years after discontinuation of treatment.
    Fjellestad-Paulsen A, Simon D, Czernichow P.
    J Clin Endocrinol Metab; 2004 Mar 09; 89(3):1234-9. PubMed ID: 15001616
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.